Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma.
hepatocellular carcinoma
locoregional therapy
microwave ablation
necrosis
percutaneous techniques
radiofrequency ablation
survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
25 02 2021
25 02 2021
Historique:
received:
29
12
2020
revised:
27
01
2021
accepted:
19
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Contrasting data are available in the literature regarding the superiority of percutaneous microwave ablation (MWA) or radiofrequency ablation (RFA) in very early or early (BCLA 0 or A) hepatocellular carcinoma (HCC). The primary outcome was to compare the efficacy of RFA and MWA in achieving complete response in cirrhotic patients with early and very early HCC. The secondary outcomes were to evaluate the overall survival and the recurrence rate. A retrospective, observational, single-center study was performed. Inclusion criteria were liver cirrhosis, new diagnosis of a single node of HCC measuring a maximum of 50 mm or up to three nodules with diameter up to 35 mm, treatment with RFA or MWA. Radiological response was evaluated with multiphasic contrast-enhanced Computed Tomography or Magnetic Resonance Imaging at 5-7 weeks after thermal ablation. Complete response was defined when no vital tissue was detected after treatment. Overall, 251 HCC patients were included in this study; 81 patients were treated with MWA and 170 with RFA. The complete response rate was similar in MWA and RFA groups (out of 331 nodules, 87.5% (91/104) were treated with MWA and 84.2% (186/221) were treated with RFA, This study showed that MWA is more efficient than RFA in achieving complete response in HCC nodules with 21 to 35 mm diameter.
Sections du résumé
BACKGROUND
Contrasting data are available in the literature regarding the superiority of percutaneous microwave ablation (MWA) or radiofrequency ablation (RFA) in very early or early (BCLA 0 or A) hepatocellular carcinoma (HCC).
AIMS
The primary outcome was to compare the efficacy of RFA and MWA in achieving complete response in cirrhotic patients with early and very early HCC. The secondary outcomes were to evaluate the overall survival and the recurrence rate.
METHODS
A retrospective, observational, single-center study was performed. Inclusion criteria were liver cirrhosis, new diagnosis of a single node of HCC measuring a maximum of 50 mm or up to three nodules with diameter up to 35 mm, treatment with RFA or MWA. Radiological response was evaluated with multiphasic contrast-enhanced Computed Tomography or Magnetic Resonance Imaging at 5-7 weeks after thermal ablation. Complete response was defined when no vital tissue was detected after treatment.
RESULTS
Overall, 251 HCC patients were included in this study; 81 patients were treated with MWA and 170 with RFA. The complete response rate was similar in MWA and RFA groups (out of 331 nodules, 87.5% (91/104) were treated with MWA and 84.2% (186/221) were treated with RFA,
CONCLUSION
This study showed that MWA is more efficient than RFA in achieving complete response in HCC nodules with 21 to 35 mm diameter.
Identifiants
pubmed: 33669107
pii: curroncol28020101
doi: 10.3390/curroncol28020101
pmc: PMC8025753
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1034-1044Références
J Vasc Interv Radiol. 2015 Aug;26(8):1139-1146.e2
pubmed: 26027937
Cancer Epidemiol. 2015 Jun;39(3):284-90
pubmed: 25922178
Int J Hyperthermia. 2019;36(1):264-272
pubmed: 30676100
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):755-772
pubmed: 32681074
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Cardiovasc Intervent Radiol. 2020 Nov;43(11):1608-1618
pubmed: 32533309
Int J Hyperthermia. 2016 May;32(3):339-44
pubmed: 26794414
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Hepatology. 2021 Jan;73 Suppl 1:137-149
pubmed: 32557715
Gut. 2017 Jun;66(6):1172-1173
pubmed: 27884919
PLoS One. 2020 Jan 9;15(1):e0227242
pubmed: 31918433
J Clin Transl Hepatol. 2018 Sep 28;6(3):251-257
pubmed: 30271736
J Vasc Interv Radiol. 2016 May;27(5):631-8
pubmed: 27017124
Aliment Pharmacol Ther. 2018 Sep;48(6):671-681
pubmed: 30063081
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Hepatol. 2017 Feb;66(2):412-423
pubmed: 27677712
Cardiovasc Intervent Radiol. 2013 Apr;36(2):505-11
pubmed: 22572764
Eur Radiol. 2012 Sep;22(9):1983-90
pubmed: 22544225
J Hepatol. 2018 Apr;68(4):783-797
pubmed: 29031662
Clin Imaging. 2020 Nov;67:146-151
pubmed: 32659600